新型口服抗凝药的临床应用  

Clinical application of new oral anti-coagulants

作　　者：左嵩[1] 马长生[1] 

机构地区：[1]首都医科大学北京安贞医院心内科,北京100029

出　　处：《中国实用内科杂志》2016年第4期261-264,共4页Chinese Journal of Practical Internal Medicine

基　　金：科技部国际合作项目(2013DFB30310)

摘　　要：新型口服抗凝药物(NOAC)凭借其无需频繁监测凝血指标、药物食物相互作用较少、出血等并发症发生率较低等优点,在抗凝治疗中的地位不断上升。目前,NOAC已被广泛应用于非瓣膜性心房颤动、静脉血栓栓塞等病变的抗凝治疗之中。然而,针对不同的临床情况,NOAC的应用亦有其特点。文章将从NOAC的特征、临床适应证、药物间的转换及出血并发症的处理等方面阐述NOAC的应用。The status of new oral anticoagulants （NOAC） in anticoagulation therapy is rising rapidly, because of its virtue of low- frequency coagulation monitoring, fewer drug-food interactions and less incidence of bleeding. Currently, NOAC has been widely applied to anticoagulation treatment for non-valvular atrial fibrillation, venous thromboembollsm and other diseases. However, the usage of NOAC has its own characteristics according to different dinical situations. Here, we will describe the clinical features of NOAC regarding its characteristics, clinical indications, transition between anticoagulants and management of bleeding complications in clinical practice.

关 键 词：口服抗凝药 心房颤动 

分 类 号：R541.4[医药卫生—心血管疾病]